Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/08/2843184/0/en/Kymera-Therapeutics-Presents-Preclinical-Data-for-STAT6-and-TYK2-First-In-Class-Oral-Degrader-Immunology-Programs-at-the-American-Academy-of-Dermatology-Annual-Meeting.html
https://www.globenewswire.com//news-release/2024/02/28/2836786/0/en/Kymera-Therapeutics-to-Participate-in-Upcoming-March-Investor-Conferences.html
https://www.globenewswire.com//news-release/2024/02/22/2833505/0/en/Kymera-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-a-Business-Update.html
https://www.globenewswire.com//news-release/2024/02/15/2829803/0/en/Kymera-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-February-22.html
https://www.globenewswire.com/news-release/2024/01/31/2820954/0/en/Kymera-Therapeutics-to-Present-in-Fireside-Chat-at-the-Guggenheim-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2024/01/09/2806383/0/en/Kymera-Therapeutics-Outlines-Key-2024-Objectives-and-Strategy-to-Progress-Leading-Portfolio-of-Immunology-and-Oncology-Programs.html
https://www.globenewswire.com//news-release/2024/01/09/2806379/0/en/Kymera-Therapeutics-Announces-Closing-of-Upsized-275-Million-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html
https://www.globenewswire.com//news-release/2024/01/05/2804528/0/en/Kymera-Therapeutics-Announces-Pricing-of-275-Million-Public-Offering.html
https://www.globenewswire.com//news-release/2024/01/04/2804304/0/en/Kymera-Therapeutics-Announces-Proposed-Public-Offering.html
https://endpts.com/kymera-doubles-down-on-protein-degraders-for-immunology-chasing-dupixent-and-sotyktu/